Amgen (AMGN) says that based upon the recommendation of an independent Data Monitoring...
Wednesday, August 8, 2012, 4:09 PM ETAmgen (AMGN) says that based upon the recommendation of an independent Data Monitoring Committee, it's terminating its Phase 3 study of its pancreatic cancer drug Ganitumab. After reviewing the pre-planned interim analysis, the committee concluded that the drug was unlikely to demonstrate a statistically significant improvement towards the primary endpoint of overall survival. Shares -0.9% AH.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles